电邮这篇文章 Significance of damage index in prediction of systemic lupus erythematosus outcome
- 作者: Tarasova IA1, Ivanova MM1, Zhornyak AP1, Nasonova VA1
-
隶属关系:
- 期: 卷 78, 编号 1 (2003)
- 页面: 59-62
- 栏目: Editorial
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.01.2003
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29294
- ID: 29294
如何引用文章
全文:
详细
Aim. To determine the significance of the damage index (SLICC/ACR DI) in the prognosis of the outcome of systemic lupus erythematosus (SLE).
Materials and methods. Correlations between the disease activity, cumulative damage and outcome were studied in 103 patients with SLE divided into two groups by the disease duration (21 to 60 months - group 1, 62 to 488 months - group 2). SLE activity was determined by Nasonova's classification, SLEDAI-1 and ECLAM. Cumulative damage was assessed by the damage index (systemic lupus international collaborating clinics/'ACR damage index).
Results. We found the direct correlation between the age of the disease onset, SLE duration, degree of SLE activity and the damage index and between the maximal dose of glucocorticosteroids and the damage index. Conclusion. The results indicate that SLICC/ACR DI may be useful for outcome prediction in SLE.
Materials and methods. Correlations between the disease activity, cumulative damage and outcome were studied in 103 patients with SLE divided into two groups by the disease duration (21 to 60 months - group 1, 62 to 488 months - group 2). SLE activity was determined by Nasonova's classification, SLEDAI-1 and ECLAM. Cumulative damage was assessed by the damage index (systemic lupus international collaborating clinics/'ACR damage index).
Results. We found the direct correlation between the age of the disease onset, SLE duration, degree of SLE activity and the damage index and between the maximal dose of glucocorticosteroids and the damage index. Conclusion. The results indicate that SLICC/ACR DI may be useful for outcome prediction in SLE.
参考
- Насонова В. А. Системная красная волчанка. М.: Медицина; 1972.
- Gladman D. D. Prognosis and treatment of systemic lupus erythematosus. Curr. Opin. Rheumatol. 1996; 8(5): 430-437.
- Swaak A. J., Nossent J. C., Bronsveld W. et al. Systemic lupus erythematosus. 1. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann. Dis. 1989: 48: 447-454.
- Urowitz M. В., Gladman D. D. How to improve morbility and mortality in systemic lupus erythematosus. Rheumatology 2000; 39: 228-244.
- Swaak A. J., Brink H. G., Smeenk R. J. T. et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Ibid. 1999; 38: 953-958.
- Fortin P. R., Abrahamowicz M., Neville С. et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 101-107.
- Gladman D. D. The development and initial validation of the Systemic Lupus International Collaborating Clinica/American Collegge of Rheumatology (SL1CC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthr. and Rheum. 1996; 39(3): 363-369.
- Gladman D. D., Goldsmith С. H., Urowitz M. B. et al. The Systemic Lupus International Collaborating Clinica/American Collegge of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J. Rheumatol. 2000; 27(2): 373-376.
- Hanly J. G. Disease activity, cumulative damage and quality of life in SLE: results of a crosssectional study. Lupus 1997; 6: 243-247.
- Stoll Т., Stucki G., Isenberg D. A. Editorial A Damage Index for Lupus Patients - Where are we now? Ibid. 210-222.
- Mittal G., Baiacrishna C., Magnat G. et al. Sustained remission in a case of SLE following megadose cyclophosphamide. Ibid. 1999; 8: 77-80.
- Alarcon-Segovia D. Treatment needeed to achieve remission of SLE. Ibid. 566.
- Drencard C., Villa A. R., Garsia-Padilla С. et al. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75(2): 88-98.
补充文件
